All In Biotech

Drug Trial Radar · NCT06215261

An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD

An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD IMPACT-2 (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD])

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

62

Actual

Start

Apr 4, 2024

Primary completion

Sep 23, 2025

Study completion Sep 23, 2025

Sponsor

Lead sponsor
Transcend TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is evaluating the safety and efficacy of methylone in adults with PTSD. The study is conducted in two parts. * Part A is open-label and will enroll up to 15 participants with PTSD * Part B is randomized (1:1:1), single-blind and will enroll up to 45 participants with PTSD Eligible participants will enter a 3-week Treatment Period (Part A) or 4-week Treatment Period (Part B) where they will receive methylone once weekly. Following the Treatment Period, participants will enter a 6-week Follow-up Period (Part A) or 8-week Follow-up Period (Part B).

Conditions

  • Post Traumatic Stress Disorder

Interventions

  • MethyloneDrug

    Methylone capsules, given orally, once a week for 3 weeks (Part A) or 4 weeks (Part B)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Clinician-Administered PTSD Scale for the DSM-5 (CAPS-5) Total Severity ScoreTime frame: 9 weeks (Part A) / 12 weeks (Part B)

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Segal Trials

    Lauderhill, Florida

  • Accel Research

    Maitland, Florida

  • CNS Healthcare

    Orlando, Florida

  • Uptown Clinical Research

    Chicago, Illinois

  • Sunstone Medical

    Rockville, Maryland

  • Redbird Research LLC

    Las Vegas, Nevada

  • Numinus

    Draper, Utah

  • Seattle NTC

    Bellevue, Washington

  • Swinburne University of Technology

    Hawthorn, Victoria, Australia

  • Ramsay Clinic Albert Road

    Melbourne, Victoria, Australia

  • Monarch Mental Health Group

    Melbourne, Victoria, Australia

  • Clerkenwell Health

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.